Ionis Pharmaceuticals Inc (IONS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ionis Pharmaceuticals Inc (IONS) Stock Forecast
Analysts expect Ionis Pharmaceuticals (IONS) to earn -$2.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $916.49M. Of 25 analysts, 21 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 25 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 84% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 9 | 36.0% |
| Buy | 12 | 48.0% |
| Hold | 4 | 16.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 25
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 33.1%.
- Fiscal year ending Dec 31, 2026
- -$2.37
- EPS consensus, revenue $916.49M
- Fiscal year ending Dec 31, 2027
- -$1.67
- EPS consensus, revenue $1.22B
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.37 | -$2.63 to -$2.17 | 6 | $916.49M | $851.84M to $1.18B | 24 |
| Dec 31, 2027 | -$1.67 | -$2.80 to -$0.69 | 10 | $1.22B | $822.59M to $1.64B | 24 |
Quarterly Estimates
The EPS consensus rises from -$1.50 for the quarter ending Dec 31, 2026 to -$0.81 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.50 | -$1.71 to -$1.31 | 25 | $151.85M | $122.46M to $218.30M | 23 |
| Mar 31, 2027 | -$0.81 | -$0.84 to -$0.76 | 3 | $244.37M | $147.62M to $337.37M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.60.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.37 | -$2.62 | -$2.70 | -$2.70 | -$2.60 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.67 | -$1.15 | -$1.11 | -$1.11 | -$1.16 | N/A |
| Quarter ending Mar 31, 2027 | -$0.81 | -$0.83 | -$0.83 | -$0.83 | -$1.02 | N/A |
Frequently Asked Questions About IONS
What is the IONS stock forecast?
Consensus analyst estimates put Ionis Pharmaceuticals's EPS at -$2.37 for the fiscal year ending Dec 31, 2026, on revenue of $916.49M. The consensus rating from 25 analysts is Buy.
How do analysts rate IONS stock?
Of 25 analysts covering Ionis Pharmaceuticals, 9 rate it Strong Buy, 12 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IONS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.37, with estimates from -$2.63 to -$2.17 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.67, with estimates from -$2.80 to -$0.69 from 10 analysts.
What revenue do analysts expect from Ionis Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $916.49M, with estimates from $851.84M to $1.18B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.22B, with estimates from $822.59M to $1.64B.
How many analysts cover IONS?
25 analysts rate Ionis Pharmaceuticals stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IONS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors